PRINCETON, NJ - Aug 17, 2017 - mIRT  was selected in Top 100 global pharma companies after considering 2 other vendor tools. Main reason for selection was the truly configurable "no-build" option mIRT offered which led to drastic start-up time, less testing resulting in deep savings overall.

Clinical Supply management and Randomization technology is critical to any clinical trial to ensure right supplies reach patients on right time to ensure patient continuity in trial and balancing this core objective with less drug wastage. Technology vendors till date approach this with specs collections, customization, testing, UAT steps applying the traditional development model. This leads to prolonged build items and extra testing for the tool, ultimately sponsors paying the price of these inefficiencies.

mIRT is the only tool in market which proudly categorizes itself as "No-BUILD" by offering all functionality in UI configuration there by reducing build as well as UAT times there by passing higher savings to sponsors.